BioMedNewsBreaks – Lantern Pharma Inc. (NASDAQ: LTRN) to Present at RHK Capital Disruptive Growth Conference

December 2, 2022 11:45:42

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR(R) artificial intelligence (“AI””) and machine learning platform to transform the cost, pace, and timeline of oncology drug discovery and development, will be participating in the upcoming RHK Capital Disruptive Growth Conference. Slated for Dec. 5, 2022, the conference will be held in New York City. During the conference, Lantern Pharma CEO and president Panna Sharma will present; his presentation is scheduled for 12 p.m. ET. The RHK Capital Disruptive Growth Conference brings together leading C-suite executives and senior management from up to 30 growth-oriented and disruptive companies with a wide array of members from the investment community, including seasoned institutional investors, accredited investors, representatives of family offices, market analysts, financial advisors, broker-dealer wealth managers and select RHK clients.

To view the presentation, visit  

To view the full press release, visit

About Lantern Pharma Inc.

Lantern Pharma is a clinical-stage, oncology-focused biopharmaceutical company leveraging its proprietary RADR AI and machine-learning platform to discover biomarker signatures that identify patients most likely to respond to its pipeline of genomically targeted therapeutics. Lantern is currently developing four drug candidates and an ADC program across 11 disclosed tumor targets, including two phase 2 programs. By targeting drugs to patients whose genomic profile identifies them as having the highest probability of benefiting from the drug, Lantern’s approach represents the potential to deliver best-in-class outcomes. To learn more about the company, visit

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork